Sibutramine

Products and withdrawal from the market Sibutramine was approved in 1999 and was commercially available in many countries in 10- and 15-mg capsule form (Reductil, Abbott AG). On March 29, 2010, Abbott AG, in consultation with Swissmedic, informed the public that the marketing authorization had been suspended. Since then, sibutramine may no longer be prescribed … Sibutramine

Altitude Sickness

Symptoms Symptoms of altitude sickness are nonspecific and usually appear 6-10 hours after ascent. However, they can also occur after as little as one hour: Headache Dizziness Sleep disorders Loss of appetite Nausea and vomiting Fatigue and tiredness Rapid heartbeat Accelerated breathing, shortness of breath Severe symptoms: Cough Shortness of breath even at rest Tightness … Altitude Sickness

Tolcapon

Products Tolcapone is commercially available in the form of film-coated tablets (Tasmar). It has been approved in many countries since 1997. Structure and properties Tolcapone (C14H11NO5, Mr = 273.2 g/mol) exists as a yellow, odorless, non-hygroscopic, crystalline powder. It is a nitrobenzophenone. Effects Tolcapone (ATC N04BX01) affects the pharmacokinetics of levodopa. The effects are due … Tolcapon

Trimethoprim and Sulfamethoxazole

Products Trimethoprim and sulfamethoxazole are commercially available in tablet and syrup form (Bactrim, generics). The drug has been approved in many countries since 1969. The Bactrim syrup is no longer available, but a generic is available (Nopil syrup). The fixed combination of the two active ingredients is also called cotrimoxazole. Structure and properties Trimethoprim (C14H18N4O3, … Trimethoprim and Sulfamethoxazole

Psychotropic Drugs: Effects, Uses & Risks

Psychotropic drugs are a group of medications that act on the psyche of humans. Therefore, they are used to treat symptoms that occur in the context of mental disorders and neurological abnormalities. What are psychotropic drugs? Psychotropic drugs are used to treat symptoms that occur in the context of mental disorders and neurological abnormalities. Psychotropic … Psychotropic Drugs: Effects, Uses & Risks

Regorafenib

Products Regorafenib is commercially available in the form of film-coated tablets (Stivarga). It was approved in many countries in February 2013. Structure and properties Regorafenib (C21H15ClF4N4O3, Mr = 482.8 g/mol) is present in drugs as regorafenib monohydrate, which is practically insoluble in water. Effects Regorafenib (ATC L01XE21) has antitumor and antiangiogenic properties. The effects are … Regorafenib

Reboxetine

Products Reboxetine is commercially available in tablet form (Edronax). It has been approved in some European countries since 1997 and in many countries since 2000. Structure and properties Reboxetine (C19H23NO3, Mr = 313.4 g/mol) is a morpholine derivative with two chiral centers. It exists in the drug as a mixture of the ,- and ,-enantiomers. … Reboxetine

Mephedrone

Products Mephedrone has long been legally available in many countries and sold, for example, over the Internet as a plant and cactus fertilizer because it is a nitrogen compound (“The Best for Your Succulents”). E-commerce has played a major role in its distribution. It was also available in clubs and hemp stores. As of December … Mephedrone

Terbinafine (Nail Fungus)

Products Terbinafine is commercially available in tablet form (Lamisil, generic). It has been approved in many countries since 1991. Structure and properties Terbinafine (C21H25N, Mr = 291.4 g/mol) is present in drugs as terbinafine hydrochloride, a white powder that is very sparingly soluble in water. It is an allylamine and naphthalene derivative. Effects Terbinafine (ATC … Terbinafine (Nail Fungus)

Avelumab

Products Avelumab was approved in the United States, the EU, and many countries in 2017 as a concentrate for the preparation of an infusion solution (Bavencio). Structure and properties Avelumab is a human IgG1λ monoclonal antibody against programmed cell death ligand 1 (PD-L1) with a molecular weight of 147 kDa. It is produced by biotechnological … Avelumab